Sanofi $SNY Shares Sold by Atria Wealth Solutions Inc.

Key Points

• Atria Wealth Solutions Inc. significantly reduced its holdings in Sanofi by 63.4%, selling 10,055 shares, leaving them with 5,800 shares valued at $280,000.
• Sanofi's earnings report indicated an EPS of $0.90, missing the estimate of $0.96, with a revenue of $11.34 billion for the quarter, down 7% year-over-year.
• Multiple analyst upgrades have occurred recently, with Barclays maintaining an "overweight" rating and others raising their ratings; the stock currently has an average rating of "Buy" with a target price of $62.67.

Atria Wealth Solutions Inc. reduced its holdings in shares of Sanofi (NASDAQ:SNY - Free Report) by 63.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,800 shares of the company's stock after selling 10,055 shares during the period. Atria Wealth Solutions Inc.'s holdings in Sanofi were worth $280,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. Ameritas Advisory Services LLC purchased a new stake in Sanofi during the 2nd quarter valued at about $28,000. Accent Capital Management LLC purchased a new position in shares of Sanofi in the first quarter valued at approximately $29,000. Eastern Bank lifted its position in shares of Sanofi by 121.0% in the first quarter. Eastern Bank now owns 548 shares of the company's stock valued at $30,000 after acquiring an additional 300 shares in the last quarter. Banque Transatlantique SA acquired a new stake in shares of Sanofi in the first quarter valued at approximately $33,000. Finally, Golden State Wealth Management LLC increased its holdings in shares of Sanofi by 619.3% in the first quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock valued at $35,000 after purchasing an additional 545 shares during the last quarter. Hedge funds and other institutional investors own 14.04% of the company's stock.

Sanofi Stock Performance

Shares of SNY stock opened at $49.66 on Wednesday. The company has a quick ratio of 0.94, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. The stock's 50-day moving average price is $48.58 and its 200 day moving average price is $49.55. Sanofi has a 52-week low of $44.62 and a 52-week high of $60.12. The stock has a market capitalization of $121.94 billion, a PE ratio of 11.94, a price-to-earnings-growth ratio of 1.21 and a beta of 0.51.

Sanofi (NASDAQ:SNY - Get Free Report) last released its earnings results on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.96 by ($0.06). Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The business had revenue of $11.34 billion for the quarter, compared to analyst estimates of $9.91 billion. During the same quarter in the previous year, the firm posted $1.73 EPS. The business's revenue for the quarter was down 7.0% on a year-over-year basis. As a group, equities research analysts forecast that Sanofi will post 4.36 EPS for the current year.

Analyst Upgrades and Downgrades

SNY has been the subject of several recent analyst reports. Barclays reissued an "overweight" rating on shares of Sanofi in a research note on Wednesday, July 2nd. Wall Street Zen raised shares of Sanofi from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Sanofi in a report on Wednesday, October 8th. JPMorgan Chase & Co. raised shares of Sanofi from a "neutral" rating to an "overweight" rating in a research report on Friday, August 8th. Finally, Deutsche Bank Aktiengesellschaft upgraded Sanofi from a "hold" rating to a "buy" rating in a research report on Tuesday, September 2nd. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $62.67.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.